Open Access Open Access  Restricted Access Subscription Access

Nanoformulated ACE Inhibitors in Hypertension Management: A Transformative Leap Beyond Conventional Therapies

Rajgouda Patil, Bhaskar Kurangi, Gururaj V Kanabargi, Swati P Jirankali

Abstract


Hypertension remains a leading global public health challenge, contributing significantly to cardiovascular morbidity and mortality. While Angiotensin-Converting Enzyme (ACE) inhibitors have long served as a cornerstone in the pharmacologic management of hypertension, conventional formulations suffer from limitations including poor bioavailability, extensive first-pass metabolism, and side effects such as dry cough and angioedema. Recent advances in nanotechnology offer innovative solutions to these challenges. Nanoformulations including liposomes, solid lipid nanoparticles, polymeric nanoparticles, dendrimers, and nanocrystals enhance the pharmacokinetic and pharmacodynamic profiles of ACE inhibitors, allowing for targeted delivery, reduced dosing frequency, and improved patient compliance. This review provides a comprehensive analysis of the development, mechanism, pharmacological benefits, and clinical outcomes of nanoformulated ACE inhibitors. Comparisons with conventional antihypertensive therapies (e.g., beta-blockers, calcium channel blockers) highlight the superior cardiovascular protection and organ-targeted efficacy of ACE inhibitors. Nanocarrier systems demonstrate significant potential in overcoming traditional drug delivery barriers and optimizing therapeutic performance, positioning them as next-generation solutions in hypertension management.


Full Text:

PDF

References


Kumar J. Epidemiology of hypertension. Clin Queries Nephrol. 2013;2:56–61. https://doi.org/10.1016/J.CQN.2013.04.005

Guideline for the pharmacological treatment of hypertension in adults - World Health Organization - Google Books [Internet].

Aggarwal R, Chiu N, Wadhera RK, Moran AE, Raber I, Shen C, et al. Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension. 2021;78:1719–26. https://doi.org/10.1161/HYPERTENSIONAHA.121.17570/SUPPL_FILE/HYP_HYPE-2021-17570-T_SUPP1.PDF

Hazarika CR, Babu B V. Prevalence of Hypertension in Indian Tribal Population: a Systematic Review and Meta-analysis. J Racial Ethn Heal Disparities. 2024;11:451–67. https://doi.org/10.1007/S40615-023-01532-6/METRICS

Mathur P, Kulothungan V, Leburu S, Krishnan A, Chaturvedi HK, Salve HR, et al. National noncommunicable disease monitoring survey (NNMS) in India: Estimating risk factor prevalence in adult population. PLoS One. 2021;16:e0246712. https://doi.org/10.1371/JOURNAL.PONE.0246712

Leone A, Landini L, Leone A. Epidemiology and Costs of Hypertension-related Disorders. Curr Pharm Des. 2011;17:2955–72. https://doi.org/10.2174/138161211798157739/CITE/REFWORKS

Borghi C, Cicero AF, Agnoletti D, Fiorini G. Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences? Eur J Intern Med. 2023;110:10–5. https://doi.org/10.1016/J.EJIM.2023.01.005

Ahmad H, Khan H, Haque S, Ahmad S, Srivastava N, Khan A. Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension. J Renin-Angiotensin-Aldosterone Syst. 2023;2023. https://doi.org/10.1155/2023/7890188

Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol. 2018;71:1474–82. https://doi.org/10.1016/J.JACC.2018.01.058

Cutrell S, Alhomoud IS, Mehta A, Talasaz AH, Van Tassell B, Dixon DL. ACE-Inhibitors in Hypertension: A Historical Perspective and Current Insights. Curr Hypertens Rep. 2023;25:243–50. https://doi.org/10.1007/S11906-023-01248-2/METRICS


Refbacks

  • There are currently no refbacks.